NeuCyte is an innovative biotechnology company focused on CNS drug discovery.
Based on its proprietary SynFire® technology for generating human iPSC-derived neurons, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. The team is actively pursuing drug discovery programs on Fragile X Syndrome, Epilepsy, ALS and more.
NeuCyte Laboratories is the product and service division of NeuCyte. NeuCyte Labs offers iPSC-derived induced neural cells and drug discovery and nonclinical safety assessment services.